Overview

Through a series of panel discussions, presentations and workshops, Biosimilars & Biobetters USA 2015 will offer effective strategies and solutions for developing cost effective biosimilars for the future.

With an in-depth focus on the current and future landscape of the biosimilars market, this year's conference will allow input from key industry experts in the field to engage in meaningful and important discussions on how to accelerate drug development to market. With this, SMi are proud to announce that registration is now live to attend the Biosimilars and Biobetters USA conference, taking place on the 16th November to 17th November 2015 in Iselin, New Jersey, USA.

Key Speakers Include:

• Andrea Laslop, Head of Scientific Office, Austrian Agency for Health and Food Safety
• Carsten Brockmeyer, CEO, Formycon AG
• Chetak Buaria, Director, Alliance Manager, Merck Serono International S.A.
• Cliff Mintz, Senior Writer/Correspondent, Life Science Leader
• Dominic Adair, Partner, Patent Litigation, Bristows
• Gerry McGettigan, Founder & Director, Kinesys Consulting
• Jim Nelson, Senior Principal and Owner, Adversarial Proceedings/Pharma & Biotech, Schwegman Lundberg Woessner & Kluth
• John Pakulski, Senior Director and Head US Biopharmaceutical Regulatory Affairs, Sandoz Inc.
• Magdalena Leszczyniecka, Founder and CEO, STC Biologics Inc
• Michael Kleinrock, Research, Director, IMS Health Inc
• Michael Tovey, INSERM Director of Research, Laboratory of Biotechnology and Applied Pharmacology, Ecole Normale Supérieure de Cachan
• Raju Shantha, Scientific Director, Biologics Research, Janssen Pharmaceuticals, Inc.
• Rakesh Dixit, Vice President, R&D, Global Head, Biologics Safety Assessment, MedImmune Inc
• Ravi S. Harapanhalli, Vice President and Former FDA Senior Executive, Parexel International
• Richard Dicicco, Chairman, Harvest Moon Pharmaceuticals
• Robin Chadwick, Principal, Biotechnology, Schwegman Lundberg Woessner & Kluth
• Sean Xue, Director Portfolio Management, Dr Reddy’s Laboratories
• Steinar Madsen, Medical Director, Norwegian Medicines Agency
• Takashi Kei Kishimoto, Chief Scientific Officer, Selecta Biosciences

Key Benefits of Attending:

This two-day conference will focus on debate, enhanced interaction and learning objectives focussed on the below;

• Evaluating the regulatory landscape and pharmacovigilance of biosimilars
• Assessing and challenging the BPCIAs dispute resolution process
• Understanding and recognising the technical challenges in biosimilars
• Discussing how to strategically plan and revolutionise biologics manufacturing
• Reviewing the status on biosimilars - Clinical development and continued progress
• Recognising commercialization strategies & improving market development
• Developing further awareness on biobetters; are they the future?
• Examining unexpected in results in Immunogenicity testing

Event Details:
Book by 17th JULY and SAVE $400
Book by 30th SEPT and SAVE $100
For more information visit www.biosimilars-usa.com/labhoo
Contact Contact Fateja Begum via fbegum@smi-online.co.uk or +44(0)2078276184


Venue: Renaissance Woodbridge Hotel.
Location: 515 US-1, Iselin, NJ
Country: United States

Organiser Contact Details:
Julia Rotar
T: +442078276088
jrotar@smi-online.co.uk